CryoLife to start human trials of its BioGlue
This article was originally published in Clinica
Executive Summary
The FDA has told CryoLife that it can begin human trials of its BioGlue surgical adhesive for repairing aortic dissections. The Atlanta, Georgia-based company claims the product is the first in the US to be used in aortic dissections.